A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment

OBJECTIVE: Current type 2 diabetes (T2D) management contraindicates intensive glycemia treatment in patients with high cardiovascular disease (CVD) risk and is partially motivated by evidence of harms in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Heterogeneity in response...

詳細記述

保存先:
書誌詳細
出版年:Diabetes Care
主要な著者: Mariam, Arshiya, Miller-Atkins, Galen, Pantalone, Kevin M., Zimmerman, Robert S., Barnard, John, Kattan, Michael W., Shah, Hetal, McLeod, Howard L., Doria, Alessandro, Wagner, Michael J., Buse, John B., Motsinger-Reif, Alison A., Rotroff, Daniel M.
フォーマット: Artigo
言語:Inglês
出版事項: American Diabetes Association 2021
主題:
Cardiovascular and Metabolic Risk
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247498/
https://ncbi.nlm.nih.gov/pubmed/33863751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-2700
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料